Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1

Robert L. Murphy*, Jean Pierre Sommadossi, Michael Lamson, David B. Hall, Maureen Myers, Alex Dusek

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

113 Scopus citations

Abstract

Nevirapine and indinavir have the potential of affecting the pharmacokinetics of each other. In a prospective trial, 24 human immunodeficiency virus (HIV)-infected subjects on stable nucleoside or no therapy were treated with 800 mg of indinavir every 8 h. After 7 days, 200 mg of nevirapine a day was added for 14 days and then increased to 200 mg twice a day. At day 7 (before nevirapine), there was a sevenfold difference among the subjects in indinavir area under the curve (AUC), and there was a significant correlation between indinavir AUC (r2 = 0.378, P = .019), minimum plasma concentration (C(min); r2 = 0.359, P = .023), maximum plasma concentration (C(max); r2 = 0.340, P = .028), and plasma HIV RNA decline. Nevirapine significantly reduced median indinavir C(min) (47.5%) and AUC (27.4%) and, to a lesser extent, C(max) (11%). Plasma HIV RNA values were < 1/2 0 copies/mL in 10 of 17 (58.8%) subjects at 58 weeks or last visit. These data suggest that indinavir dosing should be dependent on drug exposure and not on cotherapy with nevirapine.

Original languageEnglish (US)
Pages (from-to)1116-1123
Number of pages8
JournalJournal of Infectious Diseases
Volume179
Issue number5
DOIs
StatePublished - 1999

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1'. Together they form a unique fingerprint.

Cite this